Skip to main content

Advertisement

SpringerLink
Log in

BRAF V600E Expression by Immunohistochemistry in Colon Cancer and Clinico-pathologic Features Associated with BRAF-Mutated Colonic Cancers in Mexican Patients

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

BRAF evaluation is currently limited to molecular techniques, which are expensive and not widely available to practicing pathologists. Our objective was to determine the diagnostic performance of immunohistochemistry (IHC) against BRAF V600E for BRAF mutation and the secondary objective was determining histopathological characteristics of colon carcinomas with BRAF mutated.

Methods

Cases of adenocarcinoma of the colon with a known BRAF mutation status were identified from the pathological files of our institution.

Results

We analyzed 135 cases, 13 cases had the BRAF mutation (9.6%) and 122 were non-mutated. The mutated cases expressed intense and diffusely the anti-antibody against BRAF V600E, and 119 (97.5%) of the 122 cases without mutation were negative and the remaining 3 were focal and weakly positive. The IHC demonstrated a sensitivity of 100%, specificity of 97.5%, positive predictive value of 81.3% (95% CI = 56.9 to 93.4%), negative predictive value of 100% (95% CI = 89 to 100%), and an overall accuracy of 97.8%. The only significant clinicopathological differences between cancers with BRAF mutated compared with BRAF non-mutated were that mutated had less lymph node metastases (23% vs. 68.1%) and the tumor size was greater (median 90 mm vs. 60 mm). The survival between groups was not statistically significant.

Conclusion

IHC against BRAF V600E showed an excellent performance, making it feasible as an alternative for molecular examination. Tumors with BRAF mutated did not show distinctive clinico-pathological characteristics, except for a larger tumor size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Wish TA, Hyde AJ, Parfrey PS, Green JS, Younghusband HB, Simms MI, et al. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population based study. Cancer Epidemiol Biomark Prev. 2010;19:1831–9.

    Article  CAS  Google Scholar 

  2. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010;127(2):367–80.

    CAS  PubMed  Google Scholar 

  3. De Roock W, Claes B, Bernasconi D. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62.

    Article  Google Scholar 

  4. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151–6.

    Article  CAS  Google Scholar 

  5. Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer. 2013;133:1624–30.

    Article  CAS  Google Scholar 

  6. Capper D, Berghoff AS, Magerle M, Ilhan A, Wöhrer A, Hackl M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223–33.

    Article  CAS  Google Scholar 

  7. Chen D, Huang J-F, Liu K, Zhang L-Q, Yang Z, Chuai ZR, et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014;9(3):e90607.

    Article  Google Scholar 

  8. Clancy C, Burke JP, Kalady MF, Coffey JC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Color Dis. 2013;15(12):e711–8.

    Article  CAS  Google Scholar 

  9. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J. Iacopetta B. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006;5:2.

    Article  Google Scholar 

  10. Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P. Immunohistochemistry with anti-BRAF V600E (VE1) mouse monoclonal antibody is a sensitive method for detection of the BRAF V600E mutation in colon cancer: evaluation of 120 cases with and without KRAS mutation and literature review. Pathol Oncol Res. 2017 (early online publication). https://doi.org/10.1007/s12253-017-0344-x.

    Article  Google Scholar 

  11. Affolter K, Samowitz W, Tripp S, Bronner MP. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosom Cancer. 2013;52:748–52.

    Article  CAS  Google Scholar 

  12. Bledsoe JR, Kamionek M, Mino-Kenudson M. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity. Am J Surg Pathol. 2014;38(10):1418–28.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico

    Karla J. González-Colunga & Leonardo S. Lino-Silva

  2. Gastrointestinal Pathology Division, Instituto Nacional de Cancerología de México (Mexico’s National Cancer Institute), Av. San Fernando # 22, Sección XVI, Tlalpan, 14080, Mexico City, Mexico

    Leonardo S. Lino-Silva

  3. Surgical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico

    Rosa A. Salcedo-Hernández

  4. Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico

    Erika B. Ruiz-García

  5. Surgical Oncology, Hospital Ángeles Tijuana, Tijuana, Baja California Norte, Mexico

    César Zepeda-Najar

Authors
  1. Karla J. González-Colunga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonardo S. Lino-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosa A. Salcedo-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erika B. Ruiz-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. César Zepeda-Najar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonardo S. Lino-Silva.

Ethics declarations

This study was carried out following the guidelines from Helsinski declaration and was approved for the Etics in Investigation Review Board of our Institution. Due to the retrospective nature of the study informed consent was not required.

Conflict Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

González-Colunga, K.J., Lino-Silva, L.S., Salcedo-Hernández, R.A. et al. BRAF V600E Expression by Immunohistochemistry in Colon Cancer and Clinico-pathologic Features Associated with BRAF-Mutated Colonic Cancers in Mexican Patients. J Gastrointest Canc 51, 35–40 (2020). https://doi.org/10.1007/s12029-018-00191-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-018-00191-9

Keywords

Search

Navigation